Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-06-29

Last Posted Date: 2010-05-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00346359

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Childhood Burkitt Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Anaplastic Large Cell Lymphoma
Childhood Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: ex-vivo umbilical cord blood expansion
Procedure: double-unit umbilical cord blood transplantation
Procedure: biopsy
Other: immunologic technique
Other: diagnostic laboratory biomarker analysis

First Posted Date: 2006-06-23

Last Posted Date: 2015-02-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00343798

Locations: 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Dendritic Cell Immunization
Biological: Intrathecal T-Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Intrathecal Interleukin-2
Biological: T-Cells
Biological: Interleukin-2
Drug: Mesna

First Posted Date: 2006-06-20

Last Posted Date: 2024-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1230

Registration Number: NCT00338377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2006-06-15

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 56

Registration Number: NCT00337246

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Monklands General Hospital, Airdrie, Scotland, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom

and more 13 locations

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Phase 2

Completed

Conditions: Metastatic Melanoma
Metastatic Kidney Cancer

Interventions: Drug: Natural Killer (NK) Lymphocytes
Biological: IL-2
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2006-05-22

Last Posted Date: 2012-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT00328861

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

Phase 1

Completed

Conditions: Anemia, Aplastic

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide 100mg
Drug: Cyclophosphamide 50mg
Drug: Cyclophosphamide 150mg

First Posted Date: 2006-05-16

Last Posted Date: 2021-10-28

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 97

Registration Number: NCT00326417

Locations: 🇺🇸
University of Texas, MD Anderson CRC, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 19 locations

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: Melan-A VLP vaccine, IMP321 adjuvant
Biological: adoptive immunotherapy
Biological: therapeutic autologous lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2006-05-11

Last Posted Date: 2012-11-20

Lead Sponsor: Prof. Serge Leyvraz

Target Recruit Count: 8

Registration Number: NCT00324623

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Previously Treated Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclophosphamide
Drug: cyclosporine
Drug: busulfan
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
Genetic: cytogenetic analysis
Other: flow cytometry
Other: pharmacological study
Genetic: fluorescence in situ hybridization
Drug: tacrolimus
Genetic: polymorphism analysis
Drug: methotrexate

First Posted Date: 2006-05-04

Last Posted Date: 2014-10-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00322101

Locations: 🇺🇸
Weill Cornell University, New York, New York, United States
🇺🇸
HealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Emory University, Altanta, Georgia, United States

and more 5 locations